A/Prof Marliese Alexander
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
118 Scholarly works
5 Projects
HIGHLIGHTS
2026
Journal article
Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort
DOI: 10.1016/j.cllc.2026.03.0072026
Journal article
Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
DOI: 10.1016/j.jtocrr.2026.1009782026
Journal article
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial.
DOI: 10.1093/jnci/djag0652025
Research grants (ARC, NHMRC, MRFF)
A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer
2025
Research grants (ARC, NHMRC, MRFF)
Novel Treatment of Radiation Associated Dysphagia With Statins (TRADstat)
2021
Research grants (ARC, NHMRC, MRFF)
Personalised Risk-Directed Clot Prevention for Patients With Cancer
2020
Journal article
Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
DOI: 10.1038/s41388-020-1357-6
RECENT SCHOLARLY WORKS
2026
Journal article
A Randomized Controlled Trial: Evaluating the Sleep, Cancer and Rest (SleepCaRe) Trial to Improve Health-Related Quality of Life in Women Undergoing Chemotherapy for Breast Cancer
DOI: 10.1002/pon.704182026
Journal article
Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)
DOI: 10.1016/j.jtocrr.2025.1009242026
Journal article
Diagnostic Delays in Thoracic Cancer Care: A Data-Linkage, Cohort Study between Primary Care, Hospital, and Registry Data
DOI: 10.34133/hds.04572026
Journal article
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
DOI: 10.1016/j.lungcan.2025.1088542026
Journal article
Pre-emptive DPYD genotyping and fluoropyrimidine dose optimisation: Dose tolerance and survival in cancer patients
DOI: 10.1177/107815522614459562025
Journal article
Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia
DOI: 10.1007/s40261-025-01489-w2025
Conference Proceedings
P1.17.62 Real-World Insights on Treatment Patterns and Outcomes in ROS1 NSCLC: An Australian Multicenter Study (AURORA)
DOI: 10.1016/j.jtho.2025.09.447
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
A vaLue-based Person-Centric Enhanced Health Technology Assessment in CAncer Medicine (ALPACA)